Latest post
The new Perspectives Magazine 2020 is here
The new issue of Oxurion Perspectives magazine is here. Read about last year's highlights and the ambitious times ahead.
back of the eye diseases, science community,
Progressing development of therapies for retinal vascular disorders and diabetic eye disease
Patrik De Haes, M.D., CEO of Oxurion, and Thomas Clay, Chairman of the Board, review the year 2019.
back of the eye diseases, science community,
Arshad Khanani: “Initial data of phase 1 trial of THR-687 point to clinical efficacy”
Arshad Khanani, M.D., M.A. about the clinical phase 1 data of THR-687.
back of the eye diseases, science community,
Positive phase 1 data indicate THR-687 could be an effective therapy for patients with DME
Oxurion kick-started 2020 with positive topline data from phase 1 clinical trial evaluating THR-687 for treatment of DME.
science community
A strategic focus for Oxurion: researching and developing non-VEGF pathways
Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.
science community
“An aspiring name to reflect our focus and ambition”
“The new name comes from combining the words Oxygen and Orion”, explains CEO Patrik De Haes, MD. “Raising oxygen levels in cells plays a key role in helping prevent and reverse ...